Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From DesignMedix Inc.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding column provides a comprehensive monthly review of emerging life science companies that have received VC funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced June through August 2014.
Antabio SAS is taking an antivirulence rather than an antibiotic approach to treat gram-negative nosocomial infections. When combined with marketed antibiotics, the compounds in its pipeline have potential to target key virulence pathways in pathogenic bacteria, and thus reduce patient mortality and associated costs.
VCs see rich exit opportunities, especially for start-ups with multiple products in their pipelines. In this issue we profile four emerging antibiotic drug developers: Cempra Pharmaceuticals, DesignMedix, Kenta Biotech and MGB Biopharma.
One of the key ways pathogens survive in patients receiving drug therapy for infection is by physically ridding their cells of the chemicals through molecular mechanisms known as efflux pumps. Given this role, biopharma researchers have been investigating compounds meant to act as efflux pump inhibitors and so increase the efficacy of existing antibacterial and other drugs. Count DesignMedix LLC. in that group. The start-up thinks its approach will eventually give rise to drugs that reverse resistance to fluoroquinolone antibiotics like Cipro, but the company is first working on a potential anti-malarial compound.